Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 4.259
Filter
1.
Vaccimonitor (La Habana, Print) ; 30(3)2021. tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1341783

ABSTRACT

Se realizó un estudio retrospectivo y observacional en pacientes con adenocarcinoma pancreático avanzado, tratados con Nimotuzumab combinado con un esquema de quimioterapia GEMOX, atendidos en el Servicio de Oncología Clínica del Hospital Clínico Quirúrgico Hermanos Ameijeiras entre 2013 y 2019 (n=118), cuyo objetivo fue evaluar la respuesta al tratamiento y la supervivencia global según variables clínicas, histopatológicas y tratamiento. Se utilizó método chi-cuadrado para la asociación de variables. Se evaluó la supervivencia global por el método de Kaplan Meier y se utilizó la prueba de Log-Rank y Breslow para la comparación de las curvas, con valor p<0.05. La tasa de control de la enfermedad fue 44,9. La mediana de supervivencia fue de 13,8 meses (IC95 por ciento:11,7-15,8). Las variables estadísticamente significativas asociadas con mayor respuesta al tratamiento y supervivencia fueron: no hábitos tabáquicos; índice plaquetas-linfocitos por debajo de 200; tumores primarios T2-T3, de localización predominantemente en cabeza pancreática; no presencia de metástasis al diagnóstico y más de seis dosis de quimioterapia o Nimotuzumab. Los pacientes con clasificación de bajo peso y albúmina sérica baja tuvieron peor supervivencia (p<0.05). En 42 pacientes se realizó una segunda línea de quimioterapia y se obtuvo supervivencia de 17,4 meses (IC95 por ciento:13,5-21,4). Las toxicidades clasificadas como grado 3-4 se reportaron en 27 pacientes (22,9 por ciento), las más frecuentemente observadas fueron: neuropatía (14,4 por ciento), neutropenia (10,2 por ciento) y trombopenia (9,3 por ciento). En condiciones de práctica clínica, con el Nimotuzumab combinado con quimioterapia GEMOX se obtuvieron óptimas tasas de control de la enfermedad y supervivencia con buen perfil de seguridad(AU)


A retrospective and observational study was carried out in patients with advanced pancreatic adenocarcinoma, treated with Nimotuzumab combined with a GEMOX chemotherapy scheme, in the Clinical Oncology Service at the Ameijeiras Hospital, between 2013 and 2019 (n =118), whose objective was to evaluate the response to the treatment and overall survival according to clinical, histopathological and treatment variables. The chi-square method was used for the association of variables. Overall survival was evaluated by the Kaplan Meier method and the Log-Rank and Breslow test for the comparison of the curves, with p <0.05. The disease control rate was 44.9. The median survival was 13.8 months (95 percent CI: 11.7-15.8). The statistically significant variables associated with greater response to treatment and survival were: no smoking habits; platelet-lymphocyte index below 200; T2-T3 primary tumors, predominantly located in the pancreatic head; no presence of metastases at diagnosis and greater than six doses of chemotherapy and Nimotuzumab. Patients classified as underweight and low serum albumin had worse survival (p <0.05). Second-line chemotherapy was performed in 42 patients and it was obtained SV of 17.4 months (95 percent CI: 13.5-21.4). Toxicities classified as grade 3-4 were reported in 27 patients (22.9 percent); the most frequently observed were: neuropathy (14.4 percent), neutropenia (10.2 perrcent) and thrombopenia (9.3 percent). Under clinical practice conditions, Nimotuzumab combined with GEMOX chemotherapy obtained optimal disease control and survival rates with a good safety profile(AU)


Subject(s)
Humans , Pancreatic Neoplasms/drug therapy , Reference Drugs , Retrospective Studies , Observational Study , Antineoplastic Agents/therapeutic use
2.
Bol. latinoam. Caribe plantas med. aromát ; 20(4): 394-405, jul. 2021. ilus
Article in English | LILACS | ID: biblio-1352427

ABSTRACT

In this study, it was aimed to determine the antioxidant and anticancer activities of Sideritis perfoliata methanolic extract (SPE) on cervical cancer cells (HeLa). Different doses (25, 50,100 and 200 µg/mL) of SPE were used to determine proliferation of HeLa cells by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) staining method. Induction of apoptosis was determined by Annexine-V and propidium iodide staining method. Interleukin (IL) 6-8 levels were measured by ELISA method. Antioxidant activities of SPE were determined by DPPH, DNA (plasmid pBR322) protecting and cellular antioxidant activity tests. Some phytochemicals of SPE were also screened by LC-MS-MS. It was determined that SPE reduced the proliferation of HeLa cells and also induced apoptosis. IL6-8 levels importantly decreased at 200 µg/mL. SPE exhibited moderately antioxidant activities in tests used. Among the phenolics identified, vanillic acid had the highest amount. As a result, it was determined to have the anticancer activity of SPE by decreasing cell proliferation, inducing apoptosis and decreasing IL6-8 in HeLa cells.


En este estudio, se tuvo como objetivo determinar las actividades antioxidantes y anticancerígenas del extracto metanólico de Sideritis perfoliata (SPE) en las células de cáncer de cuello uterino (HeLa). Se utilizaron diferentes dosis (25, 50, 100 y 200 µg/mL) de SPE para determinar la proliferación de células HeLa mediante el método de tinción con bromuro de 3-[4,5-dimetiltiazol-2-il] -2,5-difenil-tetrazolio (MTT). La inducción de apoptosis se determinó mediante el método de tinción con anexina-V y yoduro de propidio. Los niveles de interleucina (IL) 6-8 se midieron mediante el método ELISA. Las actividades antioxidantes de SPE se determinaron mediante pruebas de DPPH, protección de ADN (plásmido pBR322) y actividad antioxidante celular. Algunos fitoquímicos de SPE también se analizaron mediante LC-MS-MS. Se determinó que SPE redujo la proliferación de células HeLa y también indujo apoptosis. Los niveles de IL6-8 disminuyeron de manera importante a 200 µg/mL. SPE mostró actividades moderadamente antioxidantes en las pruebas utilizadas. Entre los fenólicos identificados, el ácido vainílico tuvo la mayor cantidad. Como resultado, se determinó que tenía la actividad anticancerígena de SPE al disminuir la proliferación celular, inducir apoptosis y disminuir la IL6-8 en las células HeLa.


Subject(s)
Plant Extracts/administration & dosage , Uterine Cervical Neoplasms , Sideritis/chemistry , Cell Proliferation/drug effects , Antioxidants/administration & dosage , Phenols/analysis , Plant Extracts/chemistry , Cell Survival , Interleukin-8/analysis , Interleukin-6/analysis , Apoptosis/drug effects , Gas Chromatography-Mass Spectrometry , Antineoplastic Agents , Antioxidants/chemistry
3.
Rev. cuba. med ; 60(2): e1510, tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1280345

ABSTRACT

Introducción: La desensibilización rápida a medicamentos induce una tolerancia temporal a los quimioterapéuticos que provocan reacciones de hipersensibilidad. Objetivo: Evaluar el protocolo de desensibilización rápida en escenario ambulatorio en pacientes que presentaron reacciones de hipersensibilidad a fármacos citotóxicos. Métodos: Se realizó un estudio observacional, y retrospectivo, de 30 pacientes con cáncer que desarrollaron reacciones de hipersensibilidad entre los años 2016 y 2018, tratados en el Hospital de Día del Servicio de Oncología del Clínico Quirúrgico Hermanos Ameijeiras. Se clasificaron según su intensidad, y se analizaron variables demográficas, características clínicas, y síntomas presentados. Se utilizó un protocolo en doce etapas basado en tres diluciones del fármaco. Se administró premedicación en todos los casos. Se realizó estadística descriptiva, y para la asociación entre variables, se utilizó la prueba estadística Chi-cuadrado. Resultados: La mediana de edad fue 54 años (23;77). Predominaron las mujeres; los menores de 60 años; tumor primario de colon; antecedentes de alergia; el oxaliplatino como fármaco más implicado; las RHS durante la infusión; e intensidad moderada. Fueron más frecuentes los síntomas cutáneos y gastrointestinales. Con la aplicación del protocolo se completó la quimioterapia planificada a los 30 pacientes (145 ciclos adicionales). Solo se presentaron ocho desensibilizaciones con reacciones leves de tipo cutáneas. El 94,5 por ciento de las desensibilizaciones no presentaron reacción alguna. Conclusiones: Constituye el primer reporte nacional de la utilización exitosa de un protocolo de desensibilización rápida a citostáticos que demostró ser eficaz y seguro en el escenario ambulatorio, con un manejo multidisciplinario(AU)


Introduction: Rapid desensitization to drugs induces a temporary tolerance to chemotherapeutics causing hypersensitivity reactions. Objective: To evaluate the rapid desensitization protocol in an outpatient setting in patients who had hypersensitivity reactions to cytotoxic drugs. Methods: An observational and retrospective study was carried out in 30 cancer patients, who developed hypersensitivity reactions, from 2016 to 2018. They were treated in the outpatient Oncology service at Hermanos Ameijeiras Surgical Clinical Hospital. These subjects were classified according to intensity; demographic variables, clinical characteristics, and symptoms were analyzed. A twelve-step protocol based on three dilutions of the drug was used. Premedication was administered in all cases. Descriptive statistics and for the association between variables were performed. Chi-square statistical test was used. Results: The median age was 54 years (23; 77). Predominance was observed in women, those under 60 years of age, primary colon tumor, history of allergy, oxaliplatin as the drug most implicated, HRH during infusion, and moderate intensity. Skin and gastrointestinal symptoms were more frequent. The planned chemotherapy was completed with the application of the protocol, in all 30 patients (145 additional cycles). There were only eight desensitization with mild skin-type reactions. 94.5 percent of desensitizations did not show any reaction. Conclusions: It constitutes the first national report of successful use of a rapid desensitization protocol to cytostatics that proved to be effective and safe in the outpatient setting with multidisciplinary management(AU)


Subject(s)
Humans , Female , Desensitization, Immunologic , Oxaliplatin/therapeutic use , Hypersensitivity , Antineoplastic Agents/therapeutic use , Epidemiology, Descriptive , Retrospective Studies , Observational Study
4.
Medisur ; 19(3): 503-507, 2021. graf
Article in Spanish | LILACS | ID: biblio-1287331

ABSTRACT

RESUMEN Los tumores del tracto urinario superior representan menos del 5 % de todas las neoplasias uroteliales, con un porcentaje de recurrencia superior al 90 % y una supervivencia a los 5 años que oscila entre el 30-60 %. Por tales razones se presenta el caso de un paciente de 79 años que fue ingresado en el Hospital General Universitario Dr. Gustavo Aldereguía Lima de Cienfuegos, con un cuadro clínico caracterizado por hematuria, sin otra sintomatología. Mediante estudios imagenológicos le fue diagnosticado un tumor en la pelvis del riñón derecho. Se realizó tratamiento quirúrgico, practicándose una nefrectomía total, cuyo resultado histológico fue un carcinoma de células transicionales grado II con infiltración a planos musculares. La evolución clínica fue favorable luego de un año de la cirugía. Podemos concluir que en el diagnóstico precoz tienen un papel fundamental las imágenes tomográficas, pues permitieron identificar un tumor de las vías excretoras urinarias superiores en pelvis renal derecha. Se trazó una estrategia terapéutica inicialmente quirúrgica y a continuación quimioterapia; se logró una evolución satisfactoria y contribuir a la sobrevida de este paciente.


ABSTRACT Upper urinary tract tumors represent less than 5% of all urothelial neoplasms, with a recurrence rate greater than 90% and a 5-year survival that ranges from 30-60%. Therefore a 79-years-old patient was admitted to the Dr. Gustavo Aldereguía Lima University General Hospital in Cienfuegos, with a medical history characterized by hematuria, without other symptoms. Through imaging studies, he was diagnosed with a tumor in the pelvis of the right kidney. Surgical treatment was performed and a total nephrectomy was performed, the histological result of which was a grade II transitional cell carcinoma with infiltration to the muscular planes. The clinical evolution was favorable one year after surgery. We conclude that tomographic images play a fundamental role in early diagnosis, since they allowed the identification of a tumor of the upper urinary excretory tract in the right renal pelvis. A therapeutic strategy was initially designed for surgery and then chemotherapy; a satisfactory evolution was achieved and contributes to the survival of this patient.


Subject(s)
Humans , Male , Aged , Urologic Neoplasms/diagnostic imaging , Antineoplastic Agents/therapeutic use , Clinical Evolution , Urologic Neoplasms/surgery , Survivorship
5.
J. bras. econ. saúde (Impr.) ; 13(1): 31-42, Abril/2021.
Article in Portuguese | LILACS, ECOS | ID: biblio-1252695

ABSTRACT

Objetivo: Descrever e analisar criticamente as avaliações econômicas de medicamentos antineoplásicos submetidas à Agência Nacional de Saúde Suplementar (ANS) durante o processo de atualização do rol de procedimentos em saúde 2020. Métodos: Estudo transversal de análise crítica dos estudos de avaliação econômica integrantes da documentação submetida à ANS com o objetivo de incorporação no rol de procedimentos. A avaliação da qualidade metodológica foi realizada por meio da ferramenta Methodology Checklist 6: Economic Evaluations Version 3.0 da Scottish Intercollegiate Guidelines Network. Resultados: Foram incluídas 49 avaliações econômicas: 22 estudos de custo-efetividade, 10 estudos de custo-utilidade, três estudos de custo-minimização e 14 estudos de custo-efetividade e custo-utilidade. A qualidade metodológica foi considerada, na maior parte (88%), como aceitável ou de baixa qualidade. Conclusão: Estudos de avaliação econômica são fundamentais no processo decisório de incorporação de tecnologias na saúde suplementar. Esta análise crítica sugere que a qualidade dos estudos econômicos apresentados dentro das propostas de incorporação de antineoplásicos durante o processo de atualização do rol 2020 da ANS foi limitada. Inconsistências metodológicas e falta de um relato transparente reduzem a validade e a aplicabilidade dos achados na tomada de decisão.


Objective: To describe and critically appraise the economic evaluations of antineoplastic drugs submitted to the ANS during the process of updating its 2020' list of procedures. Methods: Cross-sectional study of critical analysis of the economic evaluation studies included in the documentation submitted to the ANS with the aim of incorporating them into the list of procedures. The methodological quality assessment was carried out using the Methodology Checklist 6: Economic Evaluations Version 3.0 of the Scottish Intercollegiate Guidelines Network. Results: Overall, 49 economic evaluations were included: 22 cost-effectiveness studies, 10 cost-utility studies, three cost-minimization studies and 14 mixed economic studies. Methodological quality was mostly considered as acceptable or low quality. Conclusion: Economic evaluation studies are fundamental in the decision-making process of incorporating technologies into supplementary health care. This critical appraisal suggests that the quality of the economic studies presented within the proposals to incorporate antineoplastics during the process of updating the ANS 2020 roll was limited. Methodological inconsistencies and lack of transparent reporting reduce the validity and applicability of findings for decision-making


Subject(s)
Decision Making , Health Care Economics and Organizations , Cost-Effectiveness Evaluation , Neoplasms , Antineoplastic Agents
6.
Rev. urug. cardiol ; 36(1): e36107, abr. 2021. ilus, tab
Article in Spanish | LILACS, BNUY, UY-BNMED | ID: biblio-1252372

ABSTRACT

Las nuevas terapias oncológicas han logrado aumentar la sobrevida del paciente con cáncer, observando, sin embargo, un incremento de la morbilidad y mortalidad vinculadas a sus efectos secundarios. El desarrollo de eventos cardiovasculares adversos impacta negativamente en el pronóstico durante el tratamiento del cáncer, pero también en los supervivientes al cáncer, donde las enfermedades cardiovasculares (ECV) y las segundas neoplasias son la principal causa de muerte1-5. La cardiotoxicidad inducida por el tratamiento del cáncer se define como el conjunto de ECV derivadas de los tratamientos oncológicos. Su manifestación es variada e incluye el desarrollo de disfunción ventricular, insuficiencia cardíaca (IC), isquemia miocárdica, hipertensión arterial y arritmias, entre otras. Puede ser consecuencia tanto del efecto directo del tratamiento sobre la estructura y función cardíacas, como del desarrollo acelerado de ECV6-9. Frecuentemente se utiliza el término cardiotoxicidad como sinónimo de disfunción ventricular por quimioterapia (DV-QT). Dado que la cardiotoxicidad abarca un espectro más amplio de afectación cardiovascular, creemos conveniente hablar de DV-QT para referirnos a la afectación de la función sistólica del ventrículo izquierdo. La DV-QT y el desarrollo de IC representan una de las complicaciones más temidas por su impacto pronóstico en la esfera cardiovascular y oncológica, dado que limitan el arsenal terapéutico para el tratamiento del cáncer5,10. Han sido creadas diversas sociedades de cardio-onco-hematología con el fin de generar recomendaciones de práctica clínica y formar profesionales capacitados para el manejo de las complicaciones cardiovasculares del tratamiento del cáncer11. La cardio-oncología es una disciplina en creciente y continuo desarrollo. Creemos que es fundamental realizar tareas de formación médica continua, así como también estimular el trabajo conjunto de diversas especialidades para brindar una mejor asistencia. Este texto es el resultado del trabajo de un equipo multidisciplinario que incluye cardiólogos, hematólogos y oncólogos, y pretende brindar información a los integrantes del equipo de salud involucrados en la asistencia de pacientes oncológicos. Debido a su extensión, hemos decidido fraccionar el contenido en tres partes para facilitar su publicación.


New oncological therapies have been successful in increasing cancer patient survival, but they have also led to an increase in morbidity and mortality linked to their side effects. During cancer treatment, the development of cardiovascular side effects has a negative impact in prognosis, but also in cancer survivors, in whom cardiovascular diseases and secondary malignancies are the main cause of death. Cancer related cardiotoxicity is defined as the development of cardiovascular diseases related to cancer treatment. Clinical presentation is broad involving ventricular dysfunction, heart failure, myocardial ischemia, arterial hypertension and arrhythmias among others. This may result from the direct cardiovascular effect of a cancer treatment or accelerated development of cardiovascular diseases. Frequently, in the literature cardiotoxicity and chemotherapy related ventricular dysfunction are used as synonyms. However, cardiotoxicity includes a broad spectrum of cardiovascular manifestations, thus in this text we refer to chemotherapy related ventricular dysfunction as the presence of left ventricular systolic impairment. Chemotherapy related ventricular dysfunction and heart failure are two of the most feared complications of cancer treatment due to its impact on cardiovascular and oncological prognosis, affecting treatment options. Numerous worldwide cardio-onco-hematology societies have emerged to generate clinical practice guidelines and improve the diagnosis and evaluation of cardiovascular cancer treatment side effects. Cardio-Oncology is a discipline in continuous growth and development. We strongly believe that continuum medical education and a multidisciplinary approach is necessary to provide a quality health care. This text is the result of a multidisciplinary work involving cardiologists, hematologists and oncologists. It is our goal to provide information to the health care team involved in the assistance of cancer patients. Due to its extension, it will be published in three parts.


O desenvolvimento de novas terapias oncológicas levou a um aumento na sobrevida dos pacientes, mas ao mesmo tempo traz consigo morbidades relacionadas aos tratamentos. O desenvolvimento de efeitos cardiovasculares adversos tem um impacto negativo no prognóstico dos pacientes em tratamento, bem como nos pacientes considerados curados, nos quais doença cardiovascular e malignidades secundárias são as principais causas de morte. Cardiotoxicidade relacionada ao câncer é definida como o desenvolvimento de doença cardiovascular secundária ao tratamento. A gama de apresentações clínicas é ampla, podendo se manifestar como disfunção ventricular, insuficiência cardíaca, isquemia miocárdica, hipertensão arterial, arritmias, entre outras. Isto pode ser resultante de desenvolvimento e progressão acelerados de doença cardiovascular ou por efeito direto das terapias. Frequentemente é dito na literatura que cardiotoxicidade e disfunção ventricular relacionada à quimioterapia são sinônimos. Entretanto, cardiotoxicidade engloba um amplo espectro de manifestações cardiovasculares. Neste texto, portanto, nos referimos à disfunção ventricular causada por quimioterápicos exclusivamente como a presença de disfunção sistólica ventricular esquerda. Disfunção ventricular relacionada à quimioterapia e insuficiência cardíaca são duas das mais temidas complicações do tratamento oncológico devido ao seu impacto no prognóstico cardiovascular e oncológico, podendo afetar ainda a escolha e manutenção das opções terapêuticas. Diversas sociedades cardio-onco-hematológicas surgiram ao redor do mundo com o objetivo de gerar diretriz clínicas práticas e melhorar o diagnóstico e tratamento das complicações cardiovasculares resultantes das terapias oncológicas. A cardio-oncologia é uma disciplina em contínuo crescimento e desenvolvimento. Nós acreditamos fortemente que educação médica continuada e uma abordagem multidisciplinar são necessárias para um cuidado médico de qualidade. Este texto é o resultado de um trabalho multidisciplinar envolvendo cardiologistas, hematologistas e oncologistas. Nosso objetivo é de oferecer informação à equipe de cuidados em saúde envolvido na assistência destes pacientes. Devido à sua extensão, este texto será publicado em três partes.


Subject(s)
Humans , Ventricular Dysfunction/chemically induced , Ventricular Dysfunction/prevention & control , Ventricular Dysfunction/diagnostic imaging , Cardiotoxins/adverse effects , Cardiotoxins/pharmacology , Antineoplastic Agents/adverse effects , Biomarkers , Risk Assessment , Patient Care/standards , Heart Failure/chemically induced
7.
Arch. argent. pediatr ; 119(1): 44-50, feb. 2021. tab, ilus
Article in English, Spanish | LILACS, BINACIS | ID: biblio-1147085

ABSTRACT

Objetivo. Determinar la adherencia de pacientes oncológicos pediátricos a la medicación oral del mantenimiento y conocer sus creencias sobre la medicación.Población y métodos. Durante 2018-19, se recogió información de padres, adolescentes y oncólogos en seis hospitales públicos pediátricos de la Argentina. Se administraron cuestionarios de adherencia (Simplified Medication Adherence Questionnaire) y de creencias sobre la medicación (Beliefs About Medicines Questionnaire). Se consideró adherente a quien refirió tomar la medicación sin saltear dosis y respetando el tiempo de ayuno.Resultados. N = 203 pacientes. La adherencia informada por los padres fue del 75 %; la estimada por los oncólogos, del 82 %, y la referida por adolescentes, del 45 %. Las variables que mostraron asociación con la adherencia fueron solvencia económica, diagnóstico, hospital tratante, cantidad de hijos a cargo, tratamientos oncológicos realizados y existencia de obstáculos en el cumplimiento. Esta muestra no percibía los medicamentos como dañinos, pero consideró que se los utilizaba abusivamente. La mayoría percibía la necesidad de tomar la medicación antineoplásica para mantener/recuperar la salud, pero también expresó preocupaciones. La percepción sobre la medicación fue similar entre los padres y los adolescentes, y no se asoció con el nivel de adherencia.Conclusiones. La adherencia informada por los padres en esta muestra fue del 75 %. Los padres y los pacientes percibían la medicación como necesaria y manifestaron preocupaciones vinculadas al tratamiento


Objective. To determine the adherence to oral maintenance medication among pediatric cancer patients and know their beliefs about medications.Population and methods. Information was obtained from parents, adolescents, and oncologists from six public children's hospitals of Argentina during 2018 and 2019. Questionnaires on adherence (Simplified Medication Adherence Questionnaire) and beliefs about medication (Beliefs About Medicines Questionnaire) were administered. Patients were considered adherent if they referred taking their medication without missing a dose and complying with fasting time.Results. N = 203 patients. Parent-reported adherence was 75 %; adherence estimated by oncologists, 82 %; and that referred by adolescents, 45 %. The outcome measures associated with adherence were financial solvency, diagnosis, treating hospital, number of children under the care of the caregiver, cancer treatments received, and presence of barriers in compliance. Sample subjects did not perceive medications as harmful, but considered they were overused. Most subjects perceived the necessity to take antineoplastic agents to maintain or recover their health, but also expressed their concerns. The perception about medication was similar between parents and adolescents, and was not associated with the level of adherence.Conclusions. In this sample, parent-reported adherence was 75 %. Parents and patients perceived a necessity for medication and expressed their concerns about treatment.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Medication Adherence , Treatment Adherence and Compliance , Antineoplastic Agents , Leukemia , Surveys and Questionnaires , Maintenance
8.
Arch. argent. pediatr ; 119(1): e70-e74, feb. 2021. tab, ilus
Article in Spanish | LILACS, BINACIS | ID: biblio-1147277

ABSTRACT

El cáncer papilar de tiroides es el tumor tiroideo más común en la infancia. En estadios avanzados, puede presentarse con cuadro de insuficiencia respiratoria. El tratamiento de elección es la tiroidectomía total y iodo radiactivo. En tumores irresecables, se debería considerar terapia con inhibidores multicinasa.Niña de 10 años de edad derivada por insuficiencia respiratoria progresiva. Se realizó el diagnóstico de cáncer papilar de tiroides con metástasis pulmonares. Por presentar un tumor irresecable no pasible de cirugía, se indicó el uso compasivo de lenvatinib, que mostró una rápida y favorable respuesta clínica con resolución de la insuficiencia respiratoria al noveno día del tratamiento.El diagnóstico temprano de cáncer papilar de tiroides previene la grave morbilidad respiratoria ocasionada por diagnósticos tardíos. Podría considerarse el uso de lenvatinib como alternativa previa a las terapias de primera línea (cirugía e iodo radiactivo) en casos de enfermedad con gran compromiso local y a distancia.


Papillary thyroid cancer is the most common thyroid tumor in childhood. In advanced stages, it can present with respiratory failure. The treatment of choice is total thyroidectomy and radioactive iodine. In cases of unresectable tumors, therapy with multikinase inhibitors should be considered. A 10-year-old girl was referred for progressive respiratory failure. A diagnosis of papillary thyroid cancer with pulmonary metastases was made. Due to the presence of an unresectable tumor not subject to surgery, the compassionate use of lenvatinib was indicated, showing a rapid and favorable clinical response with resolution of respiratory failure on the ninth day.Early diagnosis of papillary thyroid cancer prevents severe respiratory morbidity caused by late diagnoses. The use of lenvatinib should be considered as a previous step towards first-line therapies (surgery and radioactive iodine) in cases with great local and distant involvement.


Subject(s)
Humans , Female , Child , Thyroid Cancer, Papillary/drug therapy , Respiratory Insufficiency , Combined Modality Therapy , Thyroid Cancer, Papillary/diagnosis , Neoplasm Metastasis , Antineoplastic Agents/therapeutic use
9.
Chinese Journal of Biotechnology ; (12): 1346-1359, 2021.
Article in Chinese | WPRIM | ID: wpr-878636

ABSTRACT

Different cell lines have different perturbation signals in response to specific compounds, and it is important to predict cell viability based on these perturbation signals and to uncover the drug sensitivity hidden underneath the phenotype. We developed an SAE-XGBoost cell viability prediction algorithm based on the LINCS-L1000 perturbation signal. By matching and screening three major dataset, LINCS-L1000, CTRP and Achilles, a stacked autoencoder deep neural network was used to extract the gene information. These information were combined with the RW-XGBoost algorithm to predict the cell viability under drug induction, and then to complete drug sensitivity inference on the NCI60 and CCLE datasets. The model achieved good results compared to other methods with a Pearson correlation coefficient of 0.85. It was further validated on an independent dataset, corresponding to a Pearson correlation coefficient of 0.68. The results indicate that the proposed method can help discover novel and effective anti-cancer drugs for precision medicine.


Subject(s)
Algorithms , Antineoplastic Agents/pharmacology , Cell Survival , Pharmaceutical Preparations
10.
Article in Chinese | WPRIM | ID: wpr-877658

ABSTRACT

OBJECTIVE@#To review systematically the effectiveness of acupuncture in treatment of chemotherapy-induced bone marrow suppression.@*METHODS@#From the date of database establishment to April 1, 2020, the articles on randomized controlled trials of chemotherapy-induced bone marrow suppression were retrieved by computer from the following databases, i.e. PubMed, Cochrane central register of controlled trials (CENTRAL), EMbase, cumulative index to nursing & allied health literature (CINAHL), JBI database of systematic reviews and implementation reports, CNKI, Wanfang, VIP and SinoMed. Using RevMan5.3, Meta-analysis was conducted. With GRADEpro GDT, the evidence quality was evaluated.@*RESULTS@#A total of 12 articles were included, 10 articles of which were analyzed by quantitative Meta-analysis. Compared with the control group, the improvements in the decrease of post-chemotherapy leukocyte (@*CONCLUSION@#Acupuncture alleviates the decrease of leukocyte, platelet, neutrophile granulocyte and erythrocyte counts and improves the survival quality of patients with chemotherapy-induced bone marrow suppression.


Subject(s)
Acupuncture Therapy , Antineoplastic Agents/adverse effects , Bone Marrow , Humans , Quality of Life , Systematic Reviews as Topic
11.
Chinese Journal of Oncology ; (12): 78-91, 2021.
Article in Chinese | WPRIM | ID: wpr-877499

ABSTRACT

Antibody-drug conjugate (ADC) is a type of targeted biological agent which connect cytotoxic drug to monoclonal antibody by a connector head, which enables monoclonal antibody acted as a carrier to efficiently transport small molecular cytotoxic drugs to target tumor cells. It is very important for clinicians to have an in-depth understanding of the molecular characteristics and mechanism of ADC drugs, rationally choose the appropriate dose, course of treatment and manage adverse reactions according to the indications during the clinical application of ADC drugs, which may even affect the survival of patients. Therefore, the consensus aims to conduct a systematic overview of commercially available ADC drugs, provide effective recommendations and references for clinicians to better apply and manage ADC drugs.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Consensus , Humans , Immunoconjugates/therapeutic use , Neoplasms/drug therapy
12.
Frontiers of Medicine ; (4): 33-42, 2021.
Article in English | WPRIM | ID: wpr-880945

ABSTRACT

Immunotherapy has recently led to a paradigm shift in cancer therapy, in which immune checkpoint inhibitors (ICIs) are the most successful agents approved for multiple advanced malignancies. However, given the nature of the non-specific activation of effector T cells, ICIs are remarkably associated with a substantial risk of immune-related adverse events (irAEs) in almost all organs or systems. Up to 90% of patients who received ICIs combination therapy experienced irAEs, of which majority were low-grade toxicity. Cytotoxic lymphocyte antigen-4 and programmed cell death protein-1/programmed cell death ligand 1 inhibitors usually display distinct features of irAEs. In this review, the mechanisms of action of ICIs and how they may cause irAEs are described. Some unsolved challenges, however really engrossing issues, such as the association between irAEs and cancer treatment response, tumor response to irAEs therapy, and ICIs in challenging populations, are comprehensively summarized.


Subject(s)
Antineoplastic Agents/adverse effects , Humans , Immune Checkpoint Inhibitors , Immunotherapy/adverse effects , Neoplasms/drug therapy
13.
Article in Chinese | WPRIM | ID: wpr-880097

ABSTRACT

OBJECTIVE@#To evaluate the clinical efficacy and safety of domestic imatinib (made in China) in patients with newly diagnosed chronic myeloid leukemia chronic phase(CML-CP).@*METHODS@#Fifty-seven newly diagnosed CML-CP patients who did not receive any other anti-CML treatment were treated by domestic imatinib 400 mg once a day. The hematological, cytogenetic and molecular reactions and safety were observed and evaluated after 3, 6 and 12 months of treatment.@*RESULTS@#Fifty-six patients were treated for ≥3 and 6 months, among which 50 patients were treated for ≥12 months. After 3 months of treatment, 49 patients underwent hematological examination, 47 patients (95.9%) achieved complete hematological response (CHR), 49 patients underwent cytogenetic examination, 39 patients (79.6%) achieved major cytogenetic response (MCyR), and 12 patients (24.5%) achieved complete cytogenetic response (CCyR). 49 patients underwent the level of BCR-ABL test, including 41 patients (83.7%) with BCR-ABL@*CONCLUSION@#In the real world, Domestics imatinib mesylate is effective and safe in the treatment of newly diagnosed CML-CP patients, but long-term follow-up data are still necessary to verify its long-term efficacy.


Subject(s)
Antineoplastic Agents/therapeutic use , Benzamides/therapeutic use , China , Fusion Proteins, bcr-abl/genetics , Humans , Imatinib Mesylate/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Piperazines , Pyrimidines/therapeutic use , Treatment Outcome
14.
Article in Portuguese | LILACS | ID: biblio-1178047

ABSTRACT

Introdução: O estado nutricional do paciente oncológico apresenta grande variação ao longo da doença, além de efeitos adversos relacionados ao trato gastrointestinal serem comuns durante o tratamento quimioterápico. Objetivo: Avaliar o estado nutricional e a presença de sintomas gastrointestinais em pacientes oncológicos submetidos à quimioterapia. Método: Estudo transversal com pacientes em tratamento no setor de Quimioterapia do Hospital Escola da Universidade Federal de Pelotas (UFPel), RS, no período de abril a julho de 2019. Dados sociodemográficos e questões relacionadas à doença foram obtidos por meio de um questionário. Para avaliação do estado nutricional e dos sintomas gastrointestinais, utilizou-se a avaliação subjetiva global produzida pelo paciente. A análise dos dados foi realizada por meio de análise descritiva, e a associação entre variáveis categóricas, verificada pelo teste qui-quadrado de Pearson (p<0,05). Resultados:Foram avaliados 101 pacientes, com média de idade de 58,6 anos e maior prevalência de indivíduos do sexo feminino (58,4%), de cor branca (77,2%), casados (53,0%), pertencentes à classe C (50,4%). Encontrou-se maior prevalência dos cânceres do trato gastrointestinal (34,6%) e mama (27,8%). A maioria dos pacientes foi classificada como bem nutrido (66,3%), enquanto saciedade precoce (56,0%), xerostomia (54,0%), inapetência (42,0%) e náusea (37,0%) foram os sintomas mais citados. Não foi encontrada associação estatística entre o estado nutricional e qualquer um dos sintomas gastrointestinais. Conclusão: O estado nutricional da maioria dos pacientes foi classificado como bem nutrido, mas necessitando de atenção para a ocorrência dos sintomas gastrointestinais.


Introduction: The nutritional status of oncologic patients varies greatly throughout the disease, further to gastrointestinal tract related adverse effects that are common during chemotherapy treatment. Objective: Evaluate the nutritional status and the presence of gastrointestinal symptoms in oncologic patients undergoing chemotherapy. Method: Cross-sectional study with patients in treatment in the Chemotherapy Unit of the Hospital School of Pelotas Federal University (UFPel), RS, from April to July 2019. Sociodemographic data and questions related to the disease were obtained through a questionnaire. To assess the nutritional status and gastrointestinal symptoms the Patient-Generated Subjective Global Assessment was utilized. Data analysis was performed through descriptive analysis, and the association between categorical variables was verified by Pearson's chi-square test (p<0.05). Results: A total of one hundred one patients was evaluated, mean age of 58.6 years, with higher prevalence of females (58.4%), Caucasian (77.2%), married (53.0%), belonging to class C (50.4%). Higher prevalence of gastrointestinal tract (34.6%) and breast (27.8%) cancer was found. Most patients were classified as well-nourished (66.3%), while early satiety (56.0%), xerostomia (54.0%), loss of apetite (42.0%), and nausea (37.0%) were the symptoms most cited. No statistical association was encountered between nutritional status and any of the gastrointestinal symptoms. Conclusion: The nutritional status of most patients was classified as well nourished, but attention is needed for the occurrence of gastrointestinal symptoms.


Introducción: El estado nutricional del paciente oncológico presenta variacones durante la enfermedad, además de los efectos adversos relacionados con el tracto gastrointestinal comunes durante la quimioterapia. Objetivo: Evaluar el estado nutricional y la presencia de síntomas gastrointestinales en pacientes con cáncer sometidos a quimioterapia. Método: Estudio transversal con pacientes tratados en el sector de quimioterapia del Hospital Escuela de la Universidad Federal de Pelotas (UFPel), RS, de abril a julio de 2019. Se obtuvieron datos sociodemográficos y relacionados con la enfermedad a través de un cuestionario. Para evaluar el estado nutricional y los síntomas gastrointestinales se utilizó la Evaluación Subjetiva Global Producida por el Paciente. Las análisis de los datos se realizó mediante análisis descriptiva, y la asociación entre variables categóricas se verificó mediante la prueba de chi-cuadrado de Pearson (p<0,05). Resultados: Se evaluaron 101 pacientes, con edad media de 58,6 años, mayor prevalencia de mujeres (58,4%), blancos (77,2%), casados (53,0%), pertenecientes a la clase C (50,4%). Se encontró una mayor prevalencia de cánceres del tracto gastrointestinal (34,6%) y de mama (27,8%). La mayoría de los pacientes se clasificó como bien nutrido (66,3%), mientras que saciedad temprana (56,0%), boca seca (54,0%), falta de apetito (42,0%) y náuseas (37,0%) fueron los síntomas más frecuentemente. No se encontró asociación estadística entre el estado nutricional y los síntomas gastrointestinales. Conclusión: El estado nutricional de la mayoría de los pacientes se clasificó como bien nutrido, pero necesita la atención a presencia de síntomas gastrointestinales.


Subject(s)
Humans , Male , Female , Nutritional Status , Drug-Related Side Effects and Adverse Reactions , Neoplasms/drug therapy , Antineoplastic Agents/adverse effects , Nutrition Assessment
15.
Rev. bras. cancerol ; 67(2): e-071133, 2021.
Article in Portuguese | LILACS | ID: biblio-1223054

ABSTRACT

Introdução: Diversos efeitos colaterais podem acometer a pele e seus anexos durante o tratamento oncológico de mulheres com câncer de mama, comprometendo a terapia. Objetivo: Identificar a ocorrência de alterações dermatológicas durante o tratamento oncológico de mulheres com câncer de mama. Método: Estudo documental e retrospectivo, de cunho quantitativo, com uso de dados secundários obtidos por meio de 190 prontuários clínicos (n=190) de um serviço privado de oncologia. Resultados: As participantes apresentaram média de idade de 53 anos (±11,2), com diagnóstico histopatológico de carcinoma ductal invasivo (85,8%). Todas foram submetidas à quimioterapia, 65,3% à mastectomia radical e 34,2% à radioterapia. As alterações dermatológicas identificadas e as ocorrências verificadas na amostra foram alopecia (94,2%), hiperpigmentação (48,4%), prurido (36,3%), eritema (6,8%), descamação (25,8%) e alterações ungueais (77,9%). Ao todo, foram identificadas 550 alterações dermatológicas, resultando em uma média de 2,9 (±1,3) por paciente. A radioterapia esteve associada a uma maior ocorrência de eritema (p<0,001) e mulheres expostas a taxanos apresentaram maior probabilidade de manifestar de alterações dermatológicas do que as não expostas (p<0,001), bem como fatores sociodemográficos não estiveram associados. Conclusão: A ocorrência de alterações dermatológicas identificadas nas participantes foi significativa, reforçando que essas manifestações podem ser frequentes em mulheres com câncer de mama durante o tratamento oncológico, requerendo medidas de prevenção e tratamento.


Introduction: Several side effects can affect the skin and its attachments during cancer treatment of women with breast cancer, compromising the therapy. Objective: To identify the occurrence of dermatological changes during cancer treatment of women with breast cancer. Method:Quantitative approach, documentary and retrospective study, using secondary data obtained from 190 clinical records (n=190) from a private oncology service. Results: The participants had a mean age of 53 years (±11.2), with histopathological diagnosis of invasive ductal carcinoma (85.8%). All participants were exposed to chemotherapy, 65.3% to radical mastectomy and 34.2% to radiotherapy. The dermatological alterations identified, and the occurrences verified in the sample were alopecia (94.2%), hyperpigmentation (48.4%), pruritus (36.3%), erythema (6.8%), desquamation (25.8%) and nail alterations (77.9%). In all, 550 dermatological alterations were identified, resulting in an average of 2.9 (±1.3) changes per patient. Radiotherapy was associated with a higher occurrence of erythema (p<0.001) and women exposed to taxanes were more likely to manifest dermatological alterations than those unexposed (p<0.001), sociodemographic factors were not associated. Conclusion: The occurrence of dermatological alterations identified in the participants was significant, reinforcing that these manifestations may be frequent in women with breast cancer during oncological treatment, requiring prevention and treatment actions.


Introducción: Varios efectos secundarios pueden afectar la piel y sus uniones durante el tratamiento del cáncer de mujeres con cáncer de mama, comprometiendo la terapia. Objetivo: Identificar la aparición de alteraciones dermatológicas durante el tratamiento del cáncer de mujeres con cáncer de mama. Método: Estudio documental y retrospectivo, de carácter cuantitativo, utilizando datos secundarios obtenidos de 190 registros clínicos (n=190) de un servicio oncológico privado. Resultados: Los participantes tenían una edad media de 53 años (±11,2), con diagnóstico histopatológico de carcinoma ductal invasivo (85,8%). Todas fueran sometidas a quimioterapia, el 65,3% a mastectomía radical y el 34,2% a radioterapia. Las alteraciones dermatológicas identificadas y las ocurrencias verificadas en la muestra fueron alopecia (94,2%), hiperpigmentación (48,4%), prurito (36,3%), eritema (6,8%), descamación (25,8%) y alteraciones en las uñas (77,9%). En total, se identificaron 550 alteraciones dermatológicas, lo que resultó en un promedio de 2,9 (±1,3) por paciente. En total, se identificaron 550 cambios dermatológicos, lo que resultó en un promedio de 2,9 (±1,3) alteraciones por paciente. La radioterapia se asoció con una mayor incidencia de eritema (p<0,001) y las mujeres expuestas a taxanos tienen más probabilidades de manifestar alteraciones dermatológicas que las no expuestas (p<0,001), además de que no se asociaron factores sociodemográficos. Conclusión: La ocurrencia de alteraciones dermatológicas identificadas en las participantes fue significativa, reforzando que estas manifestaciones pueden ser frecuentes en mujeres con cáncer de mama durante el tratamiento oncológico, requiriendo acciones de prevención y tratamiento.


Subject(s)
Radiotherapy/adverse effects , Skin Diseases , Breast Neoplasms/therapy , Antineoplastic Agents/adverse effects , Drug-Related Side Effects and Adverse Reactions/radiotherapy
16.
Rev. bras. cancerol ; 67(2): e-171189, 2021.
Article in English | LILACS | ID: biblio-1223725

ABSTRACT

Introduction: Adherence to oral antineoplastics (OA) is an important indicator of therapeutic response related to personal, social, and structural factors. Objective: To determine rates of adherence to OA, investigating possible risk factors for nonadherence and to assess patient beliefs about medication, identifying opportunities for pharmaceutical intervention. Method: An analytical study was conducted with cancer patients using OA in 2015. Adherence to Refills and Medication Scale (ARMS) and Beliefs about Medicines Questionnaire (BMQ) were applied to assess adherence and beliefs about medication and treatment. Mann-Whitney, Chi-square, and Fisher's Exact tests were used for data analysis. Results: A total of 222 patients were interviewed, with a 92.8% adherence rate according to ARMS and 84.7% according to BMQ, in which the necessity-beliefs exceeded the concerns with the treatment and use of OA. Family income, treatment interruption, number and causes of interruptions, depression, and medication possession ratio were the risk factors identified. Comparison of BMQ domains showed that, in the adherent group, patient beliefs in the necessity of the medication exceeded their concerns about it. Conclusion: Understanding the patient's beliefs is a decisive factor in comprehending the risks related to nonadherence as well as in defining strategies to deal with it.


Introdução: A adesão aos antineoplásicos orais (AO) é um importante indicador de resposta terapêutica relacionada a fatores pessoais, sociais e estruturais. Objetivo: Determinar as taxas de adesão aos AO, investigando possíveis fatores de risco para a não adesão, e avaliar as crenças dos pacientes sobre medicamentos, identificando oportunidades de intervenção farmacêutica. Método: Estudo analítico realizado com pacientes com câncer em uso de AO em 2015. Escala de Adesão e Recarga dos Medicamentos (ARMS) e Questionário de Crenças sobre Medicamentos (BMQ) foram aplicados para avaliar a adesão e crenças sobre medicamentos e tratamento. Os testes de Mann-Whitney, qui-quadrado e exato de Fisher foram usados para análise de dados. Resultados: Foram entrevistados 222 pacientes, com taxa de adesão de 92,8%, segundo o ARMS e 84,7%, segundo o BMQ, no qual as crenças de necessidade excederam as preocupações com o tratamento e o uso de AO. Renda familiar, interrupção do tratamento, número e causas das interrupções, depressão e razão de posse de medicamentos foram os fatores de risco identificados. A comparação dos domínios do BMQ demostrou que, no grupo aderente, as crenças dos pacientes sobre a necessidade do medicamento excederam suas preocupações quanto a isso. Conclusão: Considerar as crenças do paciente é um fator decisivo para compreender os riscos relacionados à não adesão, bem como para definir estratégias para lidar com ela.


Introducción: La adherencia a antineoplásicos orales (AO) es un indicador importante de la respuesta terapéutica relacionada con factores personales, sociales y estructurales. Objetivo: Determinar tasas de adherencia a AO, investigar posibles factores de riesgo de incumplimiento y evaluar creencias de los pacientes sobre la medicación, identificando oportunidades para intervención farmacéutica. Método: Estudio analítico con pacientes con cáncer que usaban AO en 2015. Se aplicó Adherencia a la Recogida y Administración de la Medicación (ARMS) y Cuestionario de Creencias sobre Medicación (BMQ) para evaluar el cumplimiento y las creencias sobre medicación y tratamiento. Las pruebas de Mann-Whitney, Chi-cuadrado y Exacto de Fisher se utilizaron para análisis de datos. Resultados: Se entrevistó un total de 222 pacientes, con una tasa de adherencia de 92,8% según ARMS y 84,7% según BMQ, en la cual las creencias de necesidad excedieron preocupaciones con el tratamiento y uso de AO. Ingreso familiar, interrupción del tratamiento, número y causas de interrupciones, depresión y proporción de posesión de medicamentos fueron los factores de riesgo identificados. La comparación de los dominios de BMQ mostró que, en el grupo adherente, las creencias sobre necesidad de la medicación excedieron preocupaciones. Conclusión: La consideración de las creencias del paciente es un factor decisivo para comprender los riesgos relacionados con la no adherencia, así como para definir estrategias para afrontarla.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Culture , Medication Adherence , Antineoplastic Agents , Pharmaceutical Services , Administration, Oral
17.
Bol. latinoam. Caribe plantas med. aromát ; 20(1): 51-60, 2021. tab, graf
Article in English | LILACS, MTYCI | ID: biblio-1145969

ABSTRACT

El extracto de cloroformo (CE) y las fracciones obtenidas de las raíces de Aldama arenaria se evaluaron para determinar su actividad antiproliferativa in vitro contra 10 líneas celulares tumorales humanas [leucemia (K-562), mama (MCF-7), ovario que expresa un fenotipo resistente a múltiples fármacos (NCI/ADR-RES), melanoma (UACC-62), pulmón (NCI-H460), próstata (PC-3), colon (HT29), ovario (OVCAR-3), glioma (U251) y riñón (786-0)]. CE presentó actividad antiproliferativa débil a moderada (log GI50 medio 1.07), mientras que las fracciones 3 y 4, enriquecidas con diterpenos de tipo pimarane [ent-pimara-8 (14), ácido 15-dien-19-oico y ent-8(14),15-pimaradien-3ß-ol], presentaron actividad moderada a potente para la mayoría de las líneas celulares, con un log GI50 medio de 0.62 y 0.59, respectivamente. Los resultados mostraron una acción antiproliferativa in vitro prometedora de las muestras obtenidas de A. arenaria, con los mejores resultados para NCI/ADR-RES, HT29 y OVCAR-3, y valores de TGI que van desde 5.95 a 28.71 µg.mL-1, demostrando que los compuestos de esta clase pueden ser prototipos potenciales para el descubrimiento de nuevos agentes terapéuticos.


Chloroform extract (CE) and fractions obtained from Aldama arenaria roots were evaluated for their in vitro antiproliferative activity against 10 human tumor cell lines [leukemia (K-562), breast (MCF-7), ovary expressing a multidrug-resistant phenotype (NCI/ADR-RES), melanoma (UACC-62), lung (NCI-H460), prostate (PC-3), colon (HT29), ovary (OVCAR-3), glioma (U251), and kidney (786-0)]. CE presented weak to moderate antiproliferative activity (mean log GI50 1.07), whereas fractions 3 and 4, enriched with pimarane-type diterpenes [ent-pimara-8(14),15-dien-19-oic acid and ent-8(14),15-pimaradien-3ß-ol], presented moderate to potent activity for most cell lines, with mean log GI50 of 0.62 and 0.59, respectively. The results showed promising in vitro antiproliferative action of the samples obtained from A. arenaria, with the best results for NCI/ADR-RES, HT29, and OVCAR-3, and TGI values ranging from 5.95 to 28.71 µg.mL-1, demonstrating that compounds of this class may be potential prototypes for the discovery of new therapeutic agents.


Subject(s)
Humans , Arenaria Plant/chemistry , Antineoplastic Agents , Plants, Medicinal , In Vitro Techniques , Brazil , Plant Extracts , Chromatography , Medicine, Traditional
18.
Rev. gaúch. enferm ; 42: e20190495, 2021. tab, graf
Article in English, Portuguese | LILACS, BDENF | ID: biblio-1156644

ABSTRACT

ABSTRACT Objective To analyze the occurrence of occlusions in peripherally inserted central venous catheters in pediatric patients in antineoplastic chemotherapy. Method Retrospective cohort, with 156 medical records of patients aged 0-19 years who underwent outpatient chemotherapy between 2013 and 2017 by this catheter, in a hospital in the city of Rio de Janeiro. Descriptive and inferential statistics were applied. Results 219 catheters were registered. Occlusion occurred in 141 (64.4%) catheters; 63 (44.7%) were removed because of occlusion, either alone or associated with another factor. Total occlusion alone led to the removal of 27 (12.3%) catheters. Occlusion was associated with: catheter dwell time, cyclophosphamide, neuroblastoma, bone metastasis and number of chemotherapy sessions. Conclusion Occlusion is an important complication because it occurred in more than half of the catheters and was one of the main reasons for withdrawal. The identified risk factors may guide the care to prevent this complication.


RESUMEN Objetivo Analizar la aparición de oclusiones en catéteres centrales de inserción periférica en niños y adolescentes sometidos a quimioterapia. Método Cohorte retrospectiva, con 156 registros de pacientes de 0 a 19 años que se sometieron a quimioterapia entre 2013 y 2017, en un hospital de Río de Janeiro. Se aplicaron estadísticas descriptivas e inferenciales. Resultados Se registraron 219 catéteres. La oclusión ocurrió en 141 (64.4%) catéteres; 63 (44.7%) se eliminaron por oclusión, ya sea solo o asociado con otro factor. La oclusión total sola condujo a la extracción de 27 (12.3%) catéteres. La oclusión se asoció con la duración de la estancia del catéter, ciclofosfamida, neuroblastoma, metástasis óseas y sesiones de quimioterapia. Conclusión La oclusión es una complicación importante, ocurrió en más de la mitad de los catéteres y fue una de las principales razones para la retirada. Los factores de riesgo pueden guiar la atención para prevenir esta complicación.


RESUMO Objetivo Analisar a ocorrência de oclusões em cateteres venosos centrais de inserção periférica nos pacientes infantojuvenis em quimioterapia antineoplásica. Método Coorte retrospectivo, com 156 prontuários de pacientes de 0 a 19 anos que realizaram quimioterapia ambulatorialmente entre 2013 e 2017 por este cateter, em hospital do município do Rio de Janeiro. Aplicou-se estatística descritiva e inferencial. Resultados Registraram-se 219 cateteres. A oclusão ocorreu em 141 (64,4%) cateteres; 63 (44,7%) foram retirados por causa da oclusão, seja isolada ou associada a outro fator. A oclusão total isoladamente foi motivo de retirada de 27 (12,3%) cateteres. A oclusão apresentou associação com: tempo de permanência do cateter, ciclofosfamida, neuroblastoma, metástase óssea e número de sessões de quimioterapia. Conclusão A oclusão é uma complicação importante, pois ocorreu em mais da metade dos cateteres e foi um dos principais motivos de retirada. Os fatores de risco identificados podem nortear o cuidado para prevenção desta complicação.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Young Adult , Central Venous Catheters/adverse effects , Neoplasms/drug therapy , Cohort Studies , Antineoplastic Agents
19.
Rev. Pesqui. (Univ. Fed. Estado Rio J., Online) ; 13: 661-665, jan.-dez. 2021. ilus
Article in English, Portuguese | LILACS, BDENF | ID: biblio-1178716

ABSTRACT

Objetivo: Identificar os estudos que descrevem a prevalência de xerostomia em pacientes com câncer de mama e em quimioterapia. Método: Revisão integrativa, partindo da questão norteadora << Quais as evidências científicas sobre a prevalência de xerostomia em pacientes com câncer de mama e em quimioterapia? >>. Foi realizada uma busca nas bases de dados: US National Library of Medicine and National Institute of Health, Literatura Latino-Americana e do Caribe em Ciências da Saúde e Scientific Electronic Library Online por meio dos Descritores em Ciências da Saúde. Foram encontrados 63 artigos, analisados por dois pesquisadores seguindo os critérios de inclusão e exclusão. Resultados: A prevalência de xerostomia foi descrita em 10 artigos que utilizaram como método de avaliação escalas, questionários com respostas dicotômicas e sialometria. Conclusão: Identificou-se uma prevalência de 47% a 77,3% de xerostomia durante a quimioterapia


Objective: To identify studies describing the prevalence of xerostomia in breast cancer patients undergoing chemotherapy. Method: Integrative review based on the guiding question << What is the scientific evidence on the prevalence of xerostomia in breast cancer patients undergoing chemotherapy? >>. We searched the US National Library of Medicine and National Institute of Health, Latin American and Caribbean Health Sciences Literature and Scientific Electronic Library Online databases using the Health Sciences Descriptors. We found 63 articles, which were analyzed by two researchers, following the inclusion and exclusion criteria. Results: The prevalence of xerostomia was described in 10 articles that used scales, questionnaires with dichotomous answers, and sialometry as evaluation methods. Conclusion: A prevalence of 47% to 77.3% of xerostomia during chemotherapy was identified


Objetivo: Identificar estudios que describen la prevalencia de xerostomía en pacientes con cáncer de mama y quimioterapia. Método: Revisión integradora, basada en la pregunta guía << ¿Cuál es la evidencia científica sobre la prevalencia de xerostomía en pacientes con cáncer de mama y quimioterapia? >>. Se realizaron búsquedas en las bases de datos US National Library of Medicine and National Institute of Health, Literatura Latino-Americana y del Caribe en Ciencias de la Salud y Scientific Electronic Library Online utilizando los Descriptores de Ciencias de la Salud. Encontramos 63 artículos, que fueron analizados por dos investigadores siguiendo los criterios de inclusión y exclusión. Resultados: La prevalencia de xerostomía se describió en 10 artículos que utilizaron escalas, cuestionarios con respuestas dicotómicas y sialometría como método de evaluación. Conclusión: Se identificó una prevalencia de xerostomía del 47% al 77,3% durante la quimioterapia


Subject(s)
Humans , Male , Female , Xerostomia/etiology , Breast Neoplasms/complications , Chemotherapy, Adjuvant/adverse effects , Prevalence , Antineoplastic Agents/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL